PHASE-I CLINICAL-STUDY OF DIHYDROXYANTHRACENEDIONE ADMINISTERED ON A 5-DAY IV SCHEDULE

Google Scholar
  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (9-10) , 841-844
Abstract
Dihydroxyanthracenedione is a new anthraquinone derivative with a wide spectrum of antitumor activity in experimental systems. A phase I clinical study was conducted using a 5-day i.v. schedule repeated every 3-4 wk. Thirty-three adults with advanced refractory solid tumors received dihydroxyanthracenedione at daily doses ranging from 0.5-4 mg/m2. Neutropenia and, to a lesser degree, thrombocytopenia were dose-limiting toxic effects, although they were of brief duration. Other toxic effects were negligible. There were no complete or partial remissions. Phase II studies of dihydroxyanthracenedione on a 5-day schedule probably should use an initial daily dose of 4 mg/m2 for good-risk patients or 2-3 mg/m2 for poor-risk patients. Treatment courses can be repeated at 4 wk intervals.